Titlebook: Coronary Artery Disease: Therapeutics and Drug Discovery; Miao Wang Book 2020 Springer Nature Singapore Pte Ltd. 2020 coronary artery dise

controllers

書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery影響因子(影響力)




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery影響因子(影響力)學(xué)科排名




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery網(wǎng)絡(luò)公開度




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery被引頻次




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery被引頻次學(xué)科排名




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery年度引用




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery年度引用學(xué)科排名




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery讀者反饋




書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery讀者反饋學(xué)科排名

Heretical

Evidence in Guidelines for Treatment of Coronary Artery Disease,is discussed, which plays an important role in CAD risk control, including forming healthy dietary pattern, maintaining proper body weight, physical exercise, smoking cessation, and so on. Part 2 elaborated on revascularization strategies and medical treatments in patients presenting with acute coro

BOLT

Revascularization for Coronary Artery Disease: Principle and Challenges,r coronary revascularization and discusses the evidence on the mechanisms, indications, techniques, and outcomes of these approaches. Targeting coronary thrombus, fibrinolysis is indicated for patients with diagnosed myocardial infarction and without high risk of severe hemorrhage. The development o

armistice

labyrinth

Lipid-Modifying Drugs: Pharmacology and Perspectives,r atherosclerosis and CAD, which results in cardiac ischemic injury and myocardial infarction. Lipid-modifying drugs can effectively improve lipid abnormalities including reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) or increasing high-density lipoprotein cholesterol (H

襲擊

襲擊

Pharmaceutical Treatment for Heart Failure, Currently, HF is divided into three groups which include HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with midrange EF (HFmrEF). Even though major advances have been made in treating HFrEF during the past decades, heart failure is a fatal disease. In

惡名聲

Drug Discovery for Coronary Artery Disease,recently approved PCSK9 inhibitors, together with antithrombotic drugs have been historically successful in reducing the occurrence of coronary artery disease (CAD), the high incidence of CAD remains imposing the largest disease burden on our healthcare systems. We reviewed cardiovascular drugs rece

reception

Book 2020ts and thrombolysis. This chapter also addresses the main therapeutic challenges..The following chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure cons

fibula

Coronary Artery Disease: Therapeutics and Drug Discovery